Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744117 | 0.80 | MAPT (0.44) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL7135870 | 0.79 | MAPT (0.52) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL616338 | 0.78 | DHODH (0.43) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL8152470 | 0.77 | MAPT (0.41) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL21858143 | 0.77 | HTR1A (0.43) | MAPTKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL7138537 | 0.76 | LTK (0.42) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL3210108 | 0.76 | ACHE (0.35) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL155112 | 0.74 | LTA4H (0.47) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL30410750 | 0.74 | LTA4H (0.47) | MAPTHPGDKDM4EL3MBTL1MEN1 | |
| SCHEMBL5533182 | 0.74 | MEN1 (0.37) | MAPTHPGDKDM4EL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114158553-B | Novel pesticide preparation and preparation method thereof | 南开沧州渤海新区绿色化工研究有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-1261336-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1261336-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-6608077-B2 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-20030055286-A1 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1261336-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001068568-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055286-A1 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | CXCL8, CCR8, CCL2 | MAPT 2058/4885HPGD 1528/4885KDM4E 3956/4885 |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | MAPT 3345/4885HPGD 630/4885KDM4E 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.